⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
[Latest] Global Terahertz Technology Market Size/Share Worth USD 3335.2 Million by 2034 at a 16.74% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
globenewswire.com
MSFT
GOOG
AMZN
NVDA
INTC
QCOM
TCEHY
BABA
CRNT
ERIC
NOK
CSCO
IBM
HPQ
DELL
ORCL
SAP
ACN
INFY
TCS
WMT
COST
HD
MCD
V
MA
JPM
BAC
WFC
GS
MS
C
AXP
CMCSA
VZ
T
TMUS
S
CHTR
NFLX
DIS
CMG
MDT
ABT
JNJ
PFE
MRK
BMY
GILD
AMGN
LLY
UNH
CVS
ANTM
CI
AET
HCA
BA
GD
LMT
RTX
BAX
ISRG
REGN
GPRO
AAPL
TSLA
F
GM
STLA
RIVN
LCID
NIO
XPEV
LI
AMD
QTRX
ALTR
XLNX
ADI
NXPI
ON
STM
WIPRO
HCLTECH
DXC
NTAP
SNPS
CDNS
MRVL
QORVO
PAWR
ETSY
EBAY
MELI
JD
BBY
LOW
PG
KO
PEP
SBUX
NKE
ADDYY
LULU
PVH
RL
GPS
TJX
MGM
LVS
WYNN
MAR
HLT
IHG
CCL
RCL
NCLH
AAL
DAL
UAL
LUV
EXPE
BKNG
PCLN
AVGO
TXN
MU
WDC
SE
SHOP
PYPL
SQ
CRM
ADBE
GOOGL
Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight
globenewswire.com
JNJ
OCGN
APLS
ALXN
IONS
BLTE
LCTX
REGN
AVNX
NBIX
STE
COG
AVD
OCUGEN
Blood Cancer United Showcases Bold Research and Vision at 2025 ASH Annual Meeting
prnewswire.com
ABBV
GILD
BMY
REGN
XBI
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
globenewswire.com
REGN
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
globenewswire.com
REGN
Geriatric Care Services Market is expected to generate a revenue of USD 2.03 Billion by 2032, Globally, at 7.98% CAGR: Verified Market Research®
globenewswire.com
ENDP
MRK
AZN
PFE
REGN
Familial Hypercholesterolemia Market Intelligence Report 2025-2035 Featuring Regeneron, Amgen, Esperion, Aegerion, Novartis and Other Key Players - Precision Medicine Fuels Personalized Treatment Approaches
globenewswire.com
REGN
AMGN
ESPR
ARWR
Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035
globenewswire.com
PFE
AZN
DSNKY
GILD
IMMU
REGN
BIIB
BMY
MRK
NVS
AMGN
LLY
JNJ
ABBV
BNTX
SEGN
RHHBY
Takeda
IQV
PE
CD38-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Darzalex Became the Number 4 Blockbuster Biologic, Just Behind Keytruda, Dupixent and Skyrizi
globenewswire.com
MRK
SNY
REGN
Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight
globenewswire.com
WEX
ATX
ASMF
VELO
WSNT
LEX
VRTX
PFE
REGN
LLY
GSK
NVO
ISPC
MRK
SCIX